Skip to main content

Author: Customer Service

Orca Energy Group Inc. Announces Completion of Q2 2025 Interim Filings

TORTOLA, British Virgin Islands, Aug. 14, 2025 (GLOBE NEWSWIRE) — Orca Energy Group Inc. (“Orca” or the “Company” and includes its subsidiaries and affiliates) (TSX-V: ORC.A, ORC.B) today announces that it has filed its condensed consolidated interim financial statements and management’s discussion and analysis for the three and six month periods ended June 30, 2025 (“Q2 2025“) with the Canadian securities regulatory authorities. All amounts are in United States dollars (“$”) unless otherwise stated. Jay Lyons, Chief Executive Officer, commented: “Operationally, Orca continues to perform in line with expectations, delivering a 9% increase in daily gas sold, compared with Q2 2024. We continue to see robust demand from our industrial customers, with sales growing in excess of 40% from H1 2024. I am also pleased...

Continue reading

Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2026

Submitted two additional U.S. government funding proposals during the quarter, bringing the total proposals to US$137 million Accepted as a new member of U.S. Medical CBRN Defense Consortium, strengthening government and biodefense partnershipsHALIFAX, Nova Scotia, Aug. 14, 2025 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the first quarter of its fiscal year 2026, which ended on June 30, 2025. All figures are in Canadian dollars unless otherwise stated. “Appili continues to strengthen our position within government and biodefense industries, highlighted by our recent participation in the U.S. Medical CBRN Defense...

Continue reading

Maui Land & Pineapple Company, Inc. Reports Fiscal Second Quarter 2025 Results

KAPALUA, Hawai‘i, Aug. 14, 2025 (GLOBE NEWSWIRE) — Maui Land & Pineapple Company, Inc. (NYSE: MLP) today reported financial results covering the quarter ended June 30, 2025. “The Company’s strong financial performance and significant revenue growth in the first half of 2025 validate our path to unlock value by maximizing the productivity of our land and commercial properties,” said Race Randle, CEO, Maui Land & Pineapple Company, Inc. “We continue to resolve legacy responsibilities and market non-strategic parcels for sale to fund projects and land improvements. Throughout the second quarter, we intentionally deployed capital to grow and diversify revenue streams, including the investment in materials and labor to launch our agave venture by planting blue weber agave on underutilized croplands in Upcounty, Maui. In addition,...

Continue reading

Flagship Communities Real Estate Investment Trust Expands Presence in Kentucky With Acquisition of 504-lot Manufactured Housing Community

Not for distribution to U.S. newswire services or dissemination in the United States. TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) — Flagship Communities Real Estate Investment Trust (TSX: MHC.U) (TSX:MHC.UN) (“Flagship” or the “REIT”) today announced it has acquired, from Empower Park, LLC (“Empower”), a 504-lot manufactured housing community (“MHC”) located in Georgetown, Kentucky (the “Acquisition”). The Acquisition is expected to be accretive to the REIT’s adjusted funds from operations (“AFFO”) per Unit and will be funded using cash on hand along with approximately $17 million in assumed debt that carries an average interest rate of 3.5%. Since 2022, Empower has made significant improvements to the MHC including the removal of approximately 50 older homes, the installation of new amenities, the re-installation of all new sewer...

Continue reading

Range Impact Reports 2Q 2025 Financial Results

Cleveland, Ohio, Aug. 14, 2025 (GLOBE NEWSWIRE) — Range Impact, Inc. (OTCQB: RNGE) (“Range Impact” or the “Company”), a public impact investing company dedicated to acquiring, reclaiming and repurposing mine sites in Appalachia, reports its results for the second quarter ended June 30, 2025. Range Impact’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 was filed with the Securities and Exchange Commission on August 14, 2025 and is available for viewing at https://rangeimpact.com/investors/. Since the information provided in this press release is limited to selected financial and operational information, shareholders and interested parties are encouraged to read the Company’s full Form 10-Q available on its website. Michael Cavanaugh, Range Impact’s CEO, states, “Our second quarter results highlight the continued...

Continue reading

XWELL Reports Second Quarter 2025 Results

NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) — XWELL, Inc. (Nasdaq: XWEL) (“XWELL” or the “Company”), a leading provider of wellness solutions for people on the go, today announced results for the second quarter ended June 30, 2025. From providing critical biosecurity support to building tech-forward wellness spaces in transportation hubs and local communities, XWELL currently is on a growth trajectory. Through its portfolio of in-airport and off-airport brands, the Company is reimagining what it means to access wellness. Operating HighlightsRevenue for the 2025 second quarter totaled $7.7 million Cost of sales decreased approximately 5% from the 2024 second quarter General and administrative expenses decreased by approximately 9% from the 2024 second quarter Named the official wellness spa of the Orlando...

Continue reading

Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity

BOSTON and ATLANTA, Aug. 14, 2025 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended June 30, 2025 and highlighted recent developments. “During our second quarter of 2025, we continued to position the Company to advance IKT-001 toward a late-stage clinical trial in PAH,” said Mark Iwicki, Chief Executive Officer of Inhibikase. “We have now finalized our study protocol, and we expect to initiate our Phase 2b clinical study of IKT-001, our re-engineered prodrug of imatinib mesylate, in PAH in the second half of 2025.” Multiple studies including both Phase 2 and the Phase 3 IMPRES...

Continue reading

Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights

PEMGARDA® (pemivibart) net product revenue of $11.8 million reported for Q2 2025, representing 413% growth year-over-year Invivyd’s target of near-term profitability (1H 2025) was not met but remains possible with the upcoming respiratory virus season Announced alignment with U.S. FDA on rapid pathway to full approval (BLA) of vaccine alternative monoclonal antibody candidate VYD2311 to protect American adults and adolescents from COVID-19 Announced attractive safety profile and pharmacokinetics data for VYD2311 from our pre-pivotal first-in-human clinical trial, including 76-day observed half-life for IM route of administration, allowing for potential long-term protectionWALTHAM, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) — Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the quarter ended June 30, 2025, and provided...

Continue reading

Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results

FDA confirms requirement for confirmatory study of roluperidone for the treatment of negative symptoms in schizophrenia Evaluation of strategic alternatives BURLINGTON, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today provided business updates. FDA Discussions & Roluperidone Update The Company has had multiple interactions with the FDA following receipt of the Complete Response Letter (CRL) for its New Drug Application (NDA) in February 2024 and the FDA has confirmed the requirement for an additional confirmatory clinical trial to address the deficiencies cited in the CRL and resubmit the NDA. As in the two previous studies (C03 and C07), the required confirmatory...

Continue reading

Actelis Networks Reports Second Quarter 2025 Financial Results and Operational Update

FREMONT, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) — Actelis Networks, Inc. (NASDAQ: ASNS) (“Actelis” or the “Company”), a market leader in cyber-hardened, rapid deployment networking solutions for IoT and broadband applications, today reported financial results for the second quarter ended June 30, 2025. “We navigated a dynamic market environment in the second quarter, while laying the groundwork for improved growth ahead, primarily in our Federal and Military verticals where we are awaiting sizeable business that was delayed in Q2 and is expected in Q3. In addition, we have accelerated and expanded our MDU market penetration efforts in more countries and more verticals,”, said Tuvia Barlev, Chairman and CEO of Actelis. “We grew 31% in revenues sequentially vs. Q1 and we are executing multiple comprehensive...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.